1 of 23

​

7.6.2025

​

Michal Pazderník

“Timing of renal replacement therapy in ICU patients“

2 of 23

AKI and Acute cardiovascular diseases

​

  • Estimated incidence rates depend on classification criteria (KDIGO, RIFLE, AKIN) => range from 25 - 47%

​

  • Large scale meta-analysis (more than 3.5 million patients)

​

    • Incidence of AKI in AHF - 36% (95% CI: 32-35%, P<0.001)

​

    • AHF patients who developed AKI had a higher risk of death than non‐AKI patients (RR, 3.65; 95% CI: 3.04–4.3)

​

  • AKI is an independent predictor of mortality in Cardiogenic Shock Registries (FRENSHOCK, CZECH-SHOCK) and in general ICU population

​

​

​

​

​

Jentzer JC, Bihorac A, Brusca SB, et al. Contemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome: JACC Council Perspectives. J Am Coll Cardiol. 2020 Sep 1;76(9):1084-1101.

Singh S, Kanwar A, Sundaragiri PR, et al. Acute Kidney Injury in Cardiogenic Shock: An Updated Narrative Review. J Cardiovasc Dev Dis. 2021 Jul 28;8(8):88.

Ru SC, Lv SB, Li ZJ. Incidence, mortality, and predictors of acute kidney injury in patients with heart failure: a systematic review. ESC Heart Fail. 2023 Dec;10(6):3237-3249.

Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015 Aug;41(8):1411-23.

Pazdernik M, Ostadal P, Seiner J, et al. Clinical characteristics, management and predictors of mortality: results from national prospective cardiogenic shock registry (CZECH-SHOCK). Eur Heart J Acute Cardiovasc Care. 2025 Feb 28:zuaf034.

3 of 23

Early RRT definition

​

  • Varies between trials:
    • Time from ICU admission:
      • Starting RRT within 6 hours of the diagnosis of KDIGO stage 3 - AKIKI trial
      • Starting RRT within 8 hours of fulfilling KDIGO stage 2 criteria – ELAIN trial
        • Plasma NGAL level: >150 ng/ml
      • Starting RRT within 12 hours after documentation of acute kidney injury – IDEAL- ICU trial
        • RIFLE criteria

​

​

​

​

​

Zarbock A, Kellum JA, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 016 May 24-31;315(20):2190-9.

Gaudry S, Hajage D, Schortgen F, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016 Jul 14;375(2):122-33.

Barbar SD, Clere-Jehl R, Bourredjem A, IDEAL-ICU Trial Investigators and the CRICS TRIGGERSEP Network. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N Engl J Med. 2018 Oct 11;379(15):1431-1442.

​

​

​

4 of 23

Pathophysiology of AKI in ACVD patients

    • Decrease in blood flow and end-organ hypoperfusion

​

    • Systemic and venous congestion (renal vein congestion - neurohormonal feedback - tubular cell injury => cardio-renal syndrome)

​

    • Mechanical circulatory support (loss of pulsatile flow, shear stress, hemolysis)

​

    • Contrast induced nephropathy (PCI, CTA,…)

​

Singh S, Kanwar A, Sundaragiri PR, et al. Acute Kidney Injury in Cardiogenic Shock: An Updated Narrative Review. J Cardiovasc Dev Dis. 2021 Jul 28;8(8):88.

​

Zarbock A, Kellum JA, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA.

Gaudry S, Hajage D, Schortgen F, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016 Jul 14;375(2):122-33.

Barbar SD, Clere-Jehl R, Bourredjem A, IDEAL-ICU Trial Investigators and the CRICS TRIGGERSEP Network. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N Engl J Med. 2018 Oct 11;379(15):1431-1442.

​

​

​

5 of 23

When to initiate early RRT?

​

Severe hyperkalemia

    • Emergency RRT for K+ >6.5 mmol/l if unresponsive to medical therapy
    • No RTCs exist defining exact hyperkalemia thresholds for RR

​

Uremia and its complications (encephalopathy, pericarditis, etc.)

    • Urea >35-40 mmol/L

​

Severe metabolic acidosis

    • IF acidosis persists despite bicarbonate, urgent RRT is required (<7.15)

​

Intoxication with dialysable toxins

    • Ethylene glycol, salicylates, methanol, barbiturates, lithium, dabigatran, etc.

​

Significant fluid overload

    • ELAIN trial: Early RRT reduced mortality in patients with PaO2/FiO2 < 300 mmHg + fluid balance > 10% of body weight
    • Other trials excluded these patients

​

​

​

Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018 Jul 7;392(10141):31-40.

​

Zarbock A, Kellum JA, Schmidt C, Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 2016 May 24-31;315(20):2190-9.

​

​

​

​

​

6 of 23

What are possible advantages of early RRT?

1. Hemodynamic Stability & Fluid Balance

​

Reduction of Venous Congestion

• AKI + volume overload → ↑ right atrial/venous pressures → myocardial stress, ↓ oxygen delivery

• CRRT → controlled fluid removal → ↓ congestion without hypotension

Interruption of Cardiorenal Syndrome

• Type 1 CRS → heart failure → AKI → fluid overload → worsening cardiac & renal function

• CRRT → breaks cycle → prevents further decline

​

​

2. Metabolic Stabilization

Correction of Electrolyte Imbalances

• Hyperkalemia → risk of malignant arrhythmias

• Other electrolytes (Na, P, Ca)→ Stabilizes cardiac & cellular function

Management of Metabolic Acidemia

• Acidemia → ↓ myocardial contractility, vasodilation, catecholamine resistance/insensitivity

Toxin Clearance

• Uremic toxins → cardiac dysfunction, immune suppression, coagulopathy

​

​

7 of 23

What are possible advantages of early RRT?

3. Inflammatory & Neurohormonal Modulation

Cytokine & Inflammatory Mediator Removal

• AKI → systemic inflammation → vasomotor dysfunction, myocardial depression

Neurohormonal Regulation

• RAAS & Sympathetic Activation → vasoconstriction, Na retention, K shifts

​

4. Prevention of multiorgan dysfunction

� Pulmonary Consequences

• Fluid overload → ↑ pulmonary capillary wedge pressure → pulmonary edema, hypoxia

​

Hepatic & Splanchnic Congestion

• Venous congestion → hepatic congestion leading to impaired function, coagulopathy, intestinal edema

Cerebral Edema & Neurological Impact

• Fluid overload + metabolic derangements → ↑ ICP, encephalopathy

​

8 of 23

​

​

​

Landmark trials

9 of 23

AKIKI trial

  • Early (immediately in KDIGO 3; n = 311) or delayed (> 72 hours oliguria/anuria or urgent indications; n = 308) initiation of RRT.

NEJM, 2016

  • No increase in mortality in delayed group
  • 50% of delayed group never needed dialysis

� 💡 Message: Many ICU patients recover kidney function without dialysis, avoiding unnecessary intervention

10 of 23

STARRT-AKI trial

  • Early (within 12 hours of diagnosis in KDIGO 2-3; n = 1465) or delayed (persistent AKI>72 hours or life threatening complications; n = 1462) initiation of RRT.
  • No difference in 90-day mortality
  • Higher dialysis dependence in early-start group�

💡 Message: No survival benefit, but higher long-term risks

NEJM, 2020

11 of 23

IDEAL-ICU trial

​

  • Early (within 12h of RIFLE-F) or delayed (delayed up to 48h or if urgent indications) strategies

​

. No mortality difference

​

. caveat: Only septic shock patients

. stopped early due to futility

​

NEJM, 2018

12 of 23

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Delayed strategy (KDIGO 3 with oliguria >72 hours or urea 40-50 mmol/L) or more delayed strategy (urea >50 mmol/l or hyperkalemia, acidosis, pulmonary edema)

  • no difference in RRT-free days = primary outcome
  • death at 60-days (HR 1.65, 95%, CI 1.09-2.50, p=0.018) in more delayed group = secondary outcome

​

​

​

​

​

​

AKIKI 2 TRIAL

Lancet, 2021

13 of 23

​

Zarbock A, Kellum JA, Schmidt C, Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 2016 May 24-31;315(20):2190-9.

​

​

​

Early RRT (≤8h after KDIGO stage 2) vs. Delayed RRT (< 12 hours of progression to KDIGO 3, or in urgent indications).

​

90-Day Mortality:�Early: 39.3%. Delayed: 54.7%. HR: 0.66 (P = .03). Absolute reduction: -15.4%.

​

Renal Recovery by Day 90:�Early: 53.6%. Delayed: 38.7%. OR: 0.55 (P = .02). Improvement: +14.9%.

Duration of RRT:�Early: Median 9 days. Delayed: Median 25 days. HR: 0.69 (P = .04).

Hospital Stay:�Early: Median 51 days. Delayed: Median 82 days. HR: 0.34 (P < .001). Reduction: -37 days.

​

14 of 23

ELAIN Trial weaknesses

​

  • Small sample

​

  • Single centered

​

  • Unblinded

​

  • Mainly postsurgical cohort

​

​

15 of 23

  • 9 RCTs with 1938 patients
  • Early RRT did not provide a survival benefit

​

But…

  • Early RRT group had significantly fewer MV days (-4 days)
  • AKI population with high plasma NGAL had favorable outcomes regarding early RRT

​

  • Need for personalized approach and risk stratification to identify patients who may benefit from early RRT

​

​

Chen JJ, Lee CC, Kuo G, et al. Comparison between watchful waiting strategy and early initiation of renal replacement therapy in the critically ill acute kidney injury population: an updated systematic review and meta-analysis. Ann Intensive Care. 2020 Mar 3;10(1):30.

​

​

​

16 of 23

NGAL

Early Biomarker for AKI:

    • NGAL detected in plasma within 2 hours of AKI; peaks at 6 hours, lasts for ~5 days.
    • Elevated serum and urine NGAL levels observed 24 hours earlier than creatinine rise.

Mechanism of Action:

    • NGAL is synthesized in response to renal tubular damage (e.g., ischemic, nephrotoxic, septic injuries).

NGAL Sources:

    • Urine NGAL: Reflects proximal tubular damage or upregulated synthesis in distal nephron segments.
    • Serum NGAL: Multifactorial, linked to neutrophil activation, liver/lung synthesis, and reduced kidney clearance.

Clinical Utility:

    • NGAL indicates renal tubular damage and may outperform serum creatinine in early AKI detection and selection of patients who may profit from early RRT
    • No clear superiority of urine vs. plasma NGAL; choice depends on lab preference.

Limitations:

    • Accuracy reduced in systemic inflammation and diseases affecting multiple organs.

​

​

Romejko K, Markowska M, Niemczyk S. The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL). Int J Mol Sci. 2023 Jun 21;24(13):10470.

​

​

​

17 of 23

  • Evaluated the effectiveness of neutrophil gelatinase-associated lipocalin (NGAL) levels in predicting acute kidney injury (AKI) necessitating renal replacement therapy (RRT)

​

  • 18 studies (1,787 patients with AKI included)

​

  • NGAL was an effective predictor of RRT need in patients with AKI

​

  • Plasma vs Urine NGAL had comparable performance

​

​

​

Xu C, Lin S, Mao L, Li Z. Neutrophil gelatinase-associated lipocalin as predictor of acute kidney injury requiring renal replacement therapy: A systematic review and meta-analysis. Front Med (Lausanne). 2022 Sep 21;9:859318.

​

​

​

18 of 23

Furosemide stress test

Furosemide Stress Test (FST)

Procedure:

• 1 mg/kg IV furosemide (1.5 mg/kg if loop diuretics were used in the prior 7 days) + fluid resuscitation

​

Criteria:

• FST-responsive: Urine output > 200 mL in 2 hours

• FST-nonresponsive: Urine output ≤ 200 mL in 2 hours

​

Results

• FST non-responders were 2.7x more likely to initiate CRRT (P=0,0001)

​

​

Zhang K, Zhang H, Zhao C, et al. The furosemide stress test predicts the timing of continuous renal replacement therapy initiation in critically ill patients with acute kidney injury: a double-blind prospective intervention cohort study. Eur J Med Res. 2023 Apr 5;28(1):149.

​

​

19 of 23

Catheters in critically ill

​

​

  • Deep venous catheters are associated with high rates of complications on the ICU - 60.9/1000 catheter-days
      • Bleeding
      • Thrombosis
      • Infections

​

Calviño Günther, Int. Care Med, 2016

20 of 23

Hypotension

  • Intermittent hemodialysis (IHD): Up to 20–30% of sessions can be complicated by intradialytic hypotension.
  • CRRT: Less likely than IHD, but still can cause hypotension — especially in critically ill, vasoplegic, or septic patients.

​

  • AKIKI Trial + STARRT-AKI => more hypotension in early group.

​

  • Mechanisms of Hypotension in Dialysis:
    • Rapid fluid removal (ultrafiltration) exceeding plasma refilling rate
    • Vasodilation due to citrate or regional anticoagulation
    • Hypoalbuminemia
    • Sepsis-related vasoplegia in ICU patients
    • Blunted compensatory sympathetic responses

21 of 23

Dialysis therapy in ICU

💰 Mean daily cost of CVVHDF is ± $2,143.

​

  • ICU dialysis is resource-intensive (machines, staff, monitoring)
  • If delayed dialysis is safe, resources can be allocated efficiently
  • Avoiding unnecessary dialysis improves ICU management

22 of 23

Key Messages

​

  • Early RRT does not consistently improve survival and may increase risks like hypotension, infections, bleeding or thrombosis.

​

  • Early RRT is effective in specific subgroups of patients (hyperkalemia, uremia, acidosis, hypervolemia, poisoning, diuretic resistance).

​

  • Many patients recover without dialysis (AKIKI trial).

​

  • Do not wait too long (AKIKI 2 trial).

​

  • Biomarkers (e.g., NGAL) and Furosemide Stress Test can help refine the timing of RRT.

​

​

​

23 of 23

Thank you for your time!